Breaking News

HHS moves to end gender-affirming care for trans youth

December 19, 2025
rose-b-avatar-teal
Disability in Health Care Reporting Fellow

Good morning. There's a ton of news today. Make sure you keep scrolling for Lizzy Lawrence's FDA exclusive on political appointees interfering with the drug review process.

I asked one of my colleagues for a sports analogy to describe Lizzy's latest run of sensational stories, but we couldn't decide on one. Is "Michael Jordan-esque" too rich?

POLITICS

HHS moves to end gender-affirming care for trans youth

Lindsey Wasson/AP

The Trump administration has announced sweeping policies that, if enacted, could effectively end gender-affirming care for transgender youth at most hospitals in the U.S. 

The Centers for Medicare and Medicaid Services proposed on Thursday two rules to withhold federal funds in connection with care for trans minors, including puberty blockers, hormones, and surgery. The most stringent rule would bar facilities that offer this care from receiving any funding from federal Medicare or Medicaid programs. It could take months or even a year for the agency to finalize the rules, which will almost certainly face legal challenges.

The attack on gender-affirming care didn't stop there. The House passed another bill today aimed at restricting gender-affirming care for trans youth, though it is not expected to pass the Senate. The Department of Health and Human Services also proposed a reversal to a 2024 Biden administration update to a landmark disability law that expanded the definition of disability to include gender dysphoria.

Patients and advocates slammed the moves, which run roughshod over decades of scientific consensus and evidence-based medicine that shows that gender-affirming care saves lives. Read more from STAT's Theresa Gaffney, Daniel Payne, and Chelsea Cirruzzo.


VACCINES

CDC's latest vaccine study … in West Africa?

The Centers for Disease Control and Prevention has awarded a $1.6 million grant to controversial researchers for a study on hepatitis B vaccines that some experts say may be unethical and is unlikely to generate data relevant to use of the vaccine in the U.S.

The agency didn't share details, but what we do know feels a bit like 2025 Health News Mad Libs: a U.S. health agency is funding a vaccine study of babies in Guinea-Bissau led by Danish researchers with ties to a top Food and Drug Administration official. The grant will fund a placebo-controlled trial of the hepatitis B vaccine in newborns. The researchers in questions have long focused on vaccines, and have faced questions from experts over some of their findings. 

The news comes weeks after a panel that advises the CDC on vaccine policy voted to recommend doing away with the country's universal hepatitis B vaccine birth dose policy. The decades-old policy, which was supported by myriad studies, has been credited with driving down rates of hepatitis B infection in U.S. babies by 99%. 

Who's the FDA official in question? Find out in this story from STAT's Helen Branswell and Lizzy Lawrence. 


DRUGS

Trump touts marijuana rescheduling, and supervised drug consumption nonprofit turns four

A drug policy two-fer from the indefatigable Lev Facher yesterday. Most notably, President Trump on Thursday signed an executive order directing the federal government to reclassify marijuana, marking a major milestone in American drug policy.

Under a new Schedule III classification, marijuana would remain illegal under federal law, but the move could facilitate additional research into cannabis. While the Trump administration cast the move as a long-awaited, commonsense measure to expand access to medical treatments, it drew swift condemnation from anti-legalization groups.

Federal marijuana rescheduling still must undergo a lengthy process to become official. The move is also unlikely to fundamentally reshape access to marijuana, either legal or illicit. Read Lev's first offering.

As Trump celebrated in the Oval Office, the nation's first nonprofit to openly offer supervised drug consumption services celebrated its fourth anniversary Thursday, following nearly a year of uncertainty and hostility from the federal government. 

In a press conference, OnPoint officials touted the organization's work, including intervening to reverse 1,983 overdoses in its consumption spaces. Their already controversial work became more tenuous this year after the White House cracked down on homelessness and threatened to withhold funding from supervised consumption sites, which it said "only facilitate illegal drug use and its attendant harm." 

Lev has you covered for more details about yesterday's celebration. 



EXCLUSIVE

FDA political appointees are reviewing drug applications

GettyImages-2241483669-1600x900Kevin Dietsch/Getty Image

Political officials are intervening in every part of the fast-track drug reviews at the Food and Drug Administration, STAT has learned, upending processes that have historically kept reviews in the hands of career scientists to ensure the safety and efficacy of drugs.

FDA Commissioner Marty Makary announced in June a pilot program to award vouchers to companies that "align with national priorities," pledging faster turnarounds on the agency's drug review. The program offered the possibility of vouchers to companies like Eli Lilly and Novo Nordisk in exchange for them lowering the cost of their weight loss drugs.

High-level officials have awarded at least one voucher to a gene therapy over the concerns of staff and have also instructed them to award vouchers to certain companies as part of the drug-pricing agreements being struck by the White House. 

If you want to know which company received a voucher over staff concerns, read more from STAT's Lizzy Lawrence.


FIRST OPINION

What underground AIDS researchers taught us

The federal response to AIDS was devastatingly slow — but it offers tremendous lessons for how to adapt to the NIH's current funding crisis, writes Robert B. Shpiner, a clinical professor of medicine at the UCLA David Geffen School of Medicine.

Instead of waiting for the perfect solution or approach to saving scientific research, opt for field medicine, says Shpiner, by triaging to keep critical systems running. He suggests formalizing underground research networks, creating state-level research bonds, and transforming how scientists receive credit.

"The AIDS research community didn't wait for President Reagan to care. We built parallel funding streams, unconventional partnerships, and new institutional models. Some failed. But enough worked that when federal money finally arrived in the '90s, we had infrastructure ready to use it effectively," he writes. Read more here.


More around STAT
Check out more exclusive coverage with a STAT+ subscription
Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

What we're reading

  •  New York is set to legalize medically assisted suicide with 'guardrails,' governor says, AP

  • Call 911 or risk losing the baby? Raids force some immigrants to avoid care, KFF Health News
  • Republicans vow bitter recriminations after Johnson outflanked on ACA, Axios

Thanks for reading! 
Rose


Enjoying Morning Rounds? Tell us about your experience
Continue reading the latest health & science news with the STAT app
Download on the App Store or get it on Google Play
STAT
STAT, 1 Exchange Place, Boston, MA
©2025, All Rights Reserved.

No comments